Repeated analysis of neuronal survival of the experiment described in Figure 1 a-d, assessed in the subiculum by Cresyl violet-staining (a), and by Neu-N + immune-reactivity (b), in which we included animals that had a motor deficit in all groups, and could not perform the cognitive test that required swimming. Anti-PD-1-treated 5XFAD mice (n = 9), and IgG-treated 5XFAD mice (n = 10), respectively;
Results are expressed as percentage of surviving neurons relative to the number of the pyramidal neurons in the age-matched the WT littermates (n = 6) controls, which were also analyzed. Data are represented as mean ± s.e.m.; * P<0.05, ** P<0.01, *** P<0.001. Supplementary Fig. 3 . Blockade of PD-L1 reduces cerebral pathology in 5XFAD mice.
Immunohistochemical analysis of the mice described in Figure 2d -g, including those that were excluded due to motor deficits in the behavior (Fig. 2c ) and the initial pathological analyses (Fig. 2e-g). (a, b) quantification of Aβ immunoreactivity in anti-PD-1-treated 5XFAD mice (n = 9), anti-PD-L1-treated 5XFAD mice (n = 10), and IgG-treated (n = 9) 5XFAD mice. (c) GFAP in anti-PD-1-treated (n = 8),
anti-PD-L1-treated 5XFAD mice (n = 10), IgG-treated (n = 15) 5XFAD mice, and WT (n=6), assessed 1 month after treatment. Mean plaque area and plaque numbers were quantified in 6-µm brain slices in the dentate gyrus (DG) and in the cerebral cortex (layer V), and GFAP immunoreactivity was measured in the hippocampus (one-way ANOVA and Fisher's exact test). 
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